2. Search Result
Search Result
Results for "

GP2

" in MedChemExpress (MCE) Product Catalog:

22

Inhibitors & Agonists

2

Peptides

1

Inhibitory Antibodies

3

Natural
Products

2

Recombinant Proteins

4

Isotope-Labeled Compounds

7

Antibodies

1

Click Chemistry

4

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-173637
    AZD0022

    		Ras Cancer
    AZD0022 is a selective and orally active KRAS G12D inhibitor. AZD0022 inhibits KRAS pathway suppression in the GP2D xenograft model .
    AZD0022
  • HY-147089
    PRRSV/CD163-IN-1

    		Bacterial Endogenous Metabolite Infection Inflammation/Immunology
    PRRSV/CD163-IN-1 is a PRRSV/CD163 inhibitor. PRRSV/CD163-IN-1 can inhibit the interaction between the PRRSV glycoprotein (GP2a or GP4) and the CD163-SRCR5 domain. PRRSV/CD163-IN-1 can be used for the research of porcine reproductive and respiratory syndrome (PRRS) .
    PRRSV/CD163-IN-1
  • HY-175870
    Eras-4001

    		Ras Cancer
    Eras-4001 (Compound 14-1) is a pan-KRAS inhibitor. Eras-4001 has potent antitumor activities and significantly inhibits the proliferation of wild-type and mutant (such as KRAS G12D, KRAS G12V and KRAS G12C) cancer cells. Eras-4001 effectively inhibits tumor growth in GP2D and Panc0403 xenograft mouse models .
    Eras-4001
  • HY-P1855
    HER2/neu (654-662) GP2

    		EGFR Cancer
    HER2/neu (654-662) GP2 is a nine amino acid peptide derived from the human epidermal growth factor receptor 2 (HER2/nue, 654–662), induces HLA-A2-restricted cytotoxic T lymphocytes (CTL) reactive to various epithelial cancers [2].
    HER2/neu (654-662) GP2
  • HY-RS05609
    GP2 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    GP2 Human Pre-designed siRNA Set A contains three designed siRNAs for GP2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    GP2 Human Pre-designed siRNA Set A
    GP2 Human Pre-designed siRNA Set A
  • HY-P991450
    ADI-15878

    ADI-15742; MBP-134 AF

    		 Filovirus Infection
    ADI-15878 is a human IgG monoclonal antibody (mAb) targeting Envelope glycoprotein, GP2. ADI-15878 can be used in Ebola virus infection research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
    ADI-15878
  • HY-U00191
    GP2-114

    		Adrenergic Receptor Cardiovascular Disease
    GP2-114 (GP-2-114) produces current-dependent cardiovascular action when administered by transdermal iontophoresis.
    GP2-114
  • HY-RS17869
    Gp2 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Gp2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Gp2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Gp2 Mouse Pre-designed siRNA Set A
    Gp2 Mouse Pre-designed siRNA Set A
  • HY-RS24338
    Gp2 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Gp2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Gp2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Gp2 Rat Pre-designed siRNA Set A
    Gp2 Rat Pre-designed siRNA Set A
  • HY-159857
    Gp(2′-5′)Ap sodium

    GP(2′-5′)Ap(3′) sodium; 2'5'-GPAp sodium; Guanylyl-(2′→5′)-3′-adenylic acid sodium

    		 Nucleoside Antimetabolite/Analog
    Gp(2′-5′)Ap sodium is a linear dinucleotide analog after hydrolysis of cyclic guanosine monophosphate- adenosine monophosphate (2’3’-cGAMP) by phosphodiesterases. Due to its linear conformation, 2’5’GpAp is intended to serve as a negative control for 2’3’-cGAMP in type I IFN induction assays.
    Gp(2′-5′)Ap sodium
  • HY-173637A
    (S)-AZD0022

    		Ras Cancer
    (S)-AZD0022 is an isomer of AZD0022, AZD0022 is a selective and orally active KRAS G12D inhibitor. AZD0022 inhibits KRAS pathway suppression in the GP2D xenograft model .
    (S)-AZD0022
  • HY-17367S4
    Atazanavir-d6

    BMS-232632-d6

    		 Isotope-Labeled Compounds HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite Infection Cancer
    Atazanavir-d6 is deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration . Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp) . Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM .
    Atazanavir-d6
  • HY-173329
    KRAS-IN-41

    		Ras Cancer
    KRAS-IN-41 is an inhibitor of KRAS with IC50 values of <0.01 μM for KRAS G12D and KRAS G12V. KRAS-IN-41 inhibits RAS mutant cell lines, GP2D (KRAS-G12D) and SW620 (KRAS-G12V). KRAS-IN-41 can be used in cancer research .
    KRAS-IN-41
  • HY-17367S2
    Atazanavir-d9

    BMS-232632-d9

    		 Isotope-Labeled Compounds HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite Infection Cancer
    Atazanavir-d9 is the deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration . Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp) . Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM .
    Atazanavir-d9
  • HY-P5695
    GP-2B

    		Bacterial Infection
    GP-2B is an antimicrobial peptide. GP-2B shows antibacterial activity against Gram-positive strain (MIC: 8-128 μg/mL for S. aureus and Enterococcus faecalis) .
    GP-2B
  • HY-W1135843
    ARN-75039

    		Arenavirus Infection
    ARN-75039 is an orally active arenavirus inhibitor. ARN-75039 binds to sites on the GP2 subunit of the mammarenavirus glycoprotein complex, stabilizes prefusion conformation, and blocks viral entry and endosomal membrane fusion to inhibit viral replication and spread. ARN-75039 can be used for the research of lassa fever, arenaviral hemorrhagic fever, and lethal Junín virus infection [2] .
    ARN-75039
  • HY-107471
    CB2 receptor agonist 3

    GP2a

    		 Cannabinoid Receptor Cancer
    CB2 receptor agonist 3 is a robust and selective CB2 cannabinoid agonist with Kis of 7.6 and 900 nM for CB2 and CB1, respectively. CB2 receptor agonist 3 significantly increases P-ERK 1/2 expression in HL-60 cells .
    CB2 receptor agonist 3
  • HY-17367S3
    Atazanavir-d5

    		Isotope-Labeled Compounds HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite Infection Cancer
    Atazanavir-d5 is the deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration . Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp) . Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM .
    Atazanavir-d5
  • HY-17367AR
    Atazanavir sulfate (Standard)

    BMS-232632 sulfate (Standard)

    		 Reference Standards HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite Infection Cancer
    Atazanavir (sulfate) (Standard) is the analytical standard of Atazanavir (sulfate). This product is intended for research and analytical applications. Atazanavir (BMS-232632) sulfate, a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration . Atazanavir sulfate is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp) . Atazanavir sulfate is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM .
    Atazanavir sulfate (Standard)
  • HY-107471R
    CB2 receptor agonist 3 (Standard)

    GP2a (Standard)

    		 Reference Standards Cannabinoid Receptor Cancer
    CB2 receptor agonist 3 (Standard) is the analytical standard of CB2 receptor agonist 3 (HY-107471). This product is intended for research and analytical applications. CB2 receptor agonist 3 is a robust and selective CB2 cannabinoid agonist with Kis of 7.6 and 900 nM for CB2 and CB1, respectively. CB2 receptor agonist 3 significantly increases P-ERK 1/2 expression in HL-60 cells .
    CB2 receptor agonist 3 (Standard)
  • HY-180885S
    KRAS G12D-IN-35

    		Ras ERK Cancer
    KRAS G12D-IN-35 (example 7) is a potent and orally active KRAS G12D inhibitor. KRAS G12D-IN-35 suppresses p-ERK in AGS cells and potently inhibits the proliferation of various KRAS G12D-mutant cancer cell lines. KRAS G12D-IN-35 inhibits tumor growth in HPAC and GP2D mouse models. KRAS G12D-IN-35 can be used for cancer research, such as pancreatic and colorectal cancer .
    KRAS G12D-IN-35
  • HY-179484
    KRASG12C IN-19

    		Reactive Oxygen Species (ROS) ERK Cancer
    KRASG12C IN-19 is a selective and orally active KRAS G12C inhibitor. KRASG12C IN-19 exerts potent antiproliferative activity against the KRAS G12C-mutant non small cell lung cancer (NSCLC) cell line H358 with an IC50 of 7.6 nM, and effectively suppresses downstream ERK phosphorylation (IC50 = 24.06 nM). KRASG12C IN 19 has no significant inhibitory activity against KRAS G12V and KRAS G12D-mutant cancer cells (PANC 1, Panc, AsPC 1, and GP2d cells) with IC50 > 10,000 nM. KRASG12C IN-19 rapidly forms a covalent bond with KRAS G12V-GDP, leading to dose-dependent inhibition of the downstream KRAS pathway. KRASG12C IN 19 can be employed for research in KRAS G12C driven cancers, including non small cell lung cancer, pancreatic cancer, and colorectal cancer .
    KRASG12C IN-19

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: